Warning (512): /home/pharma/website/current/cakephp/app/pharmalicensing/tmp/cache/ is not writable [CORE/cake/libs/cache/file.php, line 267]
Industry news
RSS Feeds
Search

Industry news

News of the day

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression

NEW YORK & BUDAPEST, Hungary, Aug 30, 2010 -- Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania. more

Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders

San Diego, February 1, 2010-- Orphagen Pharmaceuticals announced today that it has been awarded a twoyear federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian rhythm sleep disorders and more serious psychiatric illnesses, such as anxiety, depression or psychosis. The grant is a Phase 2 award within the SBIR (Small Business Innovation Research) program of the National Institutes of Health (NIH). SBIR Phase 2 grant awards are awarded... more

Industry news search

Search the Innovaro Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

© Copyright 1998-2012 Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us